Cellular immunity in cutaneous and genital HPV infections

Clinics in Dermatology

Volumn 15, Issue 2, 1997, Pages 261-274

  Malejczyk, Jacek ^a,b   Majewski, Slawomir ^a   Jabłońska, Stefania ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTATION; CELLULAR IMMUNITY; CONDYLOMA; CYTOTOXIC T LYMPHOCYTE; GENETIC POLYMORPHISM; GENITAL TRACT INFECTION; HOST RESISTANCE; HUMAN; IMMUNE STATUS; IMMUNOSURVEILLANCE; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; VIRUS CARCINOGENESIS; VIRUS EXPRESSION; WART VIRUS;

EID: 0031006126     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00049-7     Document Type: Article

References (131)

1. Wu T-C. Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 1994;6:746-54.
2. Malejczyk J, Majewski S, Jablonska S. The regulatory influence of immunological host responses. In: Gross G, von Krogh G, editors. Human papillomavirus infections in dermatovenerology. Boca Raton: CRC Press, 1997:203-26.
3. Woodworth CD, Notario V, DiPaolo JA. Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells. J Virol 1990;64:4767-75.
4. Braun L, Durst M, Mikumo R, et al. Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor β1. Cancer Res 1990;50:7324-32.
5. Nawa A, Nishyama Y, Yamamoto N, et al. Selective suppression of human papillomavirus type 18 mRNA level in HeLa cells by interferon. Biochem Biophys Res Commun 1990;170:793-9.
6. Khan MA, Tolleson WH, Gangemi JD, et al. Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons. J Virol 1993;67:3396-403.
7. Kyo S, Inoue M, Hayasaka N, et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology 1994;200:130-9.
8. Rösl F, Lengert M, Albrecht J, et al. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 1994;68:2142-50.
9. Woodworth CD, McMullin E, Iglesias M, et al. Interleukin la and tumor necrosis factor a stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci USA 1995;92: 2840-4.
10. Woodworth CD, Lichti U, Simpson S, et al. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 1992;52: 456-63.
11. Malejczyk J, Malejczyk M, Köck A, et al. Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor-α. J Immunol 1992;149:2702-08.
12. Villa LL, Vieira KBL, Pei X-F, et al. Differential effect of tumor necrosis factor on proliferation of primary human keratinocytes and cell lines containing human papillomavirus types 16 and 18. Mol Carcinog 1992;6:5-9.
13. Hagari Y, Budgeon LR, Pickel MD, et al. Association of tumor necrosis factor-α gene expression and apoptotic cell death with regression of Shope papillomas. J Invest Dermatol 1995;104:526-9.
14. Kyo S, Inoue M, Nishio Y, et al. NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region. J Virol 1993; 67:1058-66.
15. Rösl F, Das BC, Lengert M, et al. Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. J Virol 1997;71:362-70.
16. Yarden A, Kimchi A. Tumor necrosis factor reduces c-myc expression and cooperates with interferon-gamma in HeLa cells. Science 1986;234:1419-21.
17. Coleman N, Greenfield IM, Hare J, et al. Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirus-related disease of cervical keratinocytes. Am J Pathol 1993;143: 355-67.
18. Majewski S, Bretburd F, Orth G, et al. Regulation of MHC class I, class II and ICAM-1 expression by cytokines and retinoids in HPV-harboring keratinocyte lines. In: Stanley MA, editor. Immunology of human papillomaviruses. New York: Plenum Press, 1994:207-10.
19. Malejczyk J, Majewski S, Malejczyk M, et al. Autocrine tumor necrosis factor-α-mediated upregulation of intercellular adhesion molecule-1 by human papillomavirus-harboring SKv keratinocytes. (submitted).
20. Luger TA, Schwarz T. Epidermal cell-derived cytokines. In: Boss JD, editor. Skin immune system (SIS). Boca Raton: CRC Press, 1990;257-91.
21. Stadnyk AW. Cytokine production by epithelial cells. FASEB J 1994;8:1041-7.
22. Schröder J-M. Cytokine networks in the skin. J Invest Dermatol 1995;105:20S-4S.
23. Majewski S, Hunzelmann N, Nischt R, et al. TGFβ1 and TNFa expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991; 97:862-7.
24. Malejczyk J, Malejczyk M, Majewski S, et al. Increased tumorigenicity of human papillomavirus type 16-harboring keratinocytes is associated with resistance to endogenous tumor necrosis factor-α-mediated growth limitation. Int J Cancer 1994;56:593-8.
25. Malejczyk J, Malejczyk M, Urbanski A, et al. Constitutive release of IL-6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: a mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. Cell Immunol 1991;136:155-64.
26. Iglesias M, Plowman GD, Woodworth CD. Interleukin-6 and interleukin-6 soluble receptor regulate proliferation of normal, human papillomavirus-immortalized, and carcinoma-derived cervical cells in vitro. Am J Pathol 1995;146:944-52.
27. Vambutas A, Di Lorenzo TP, Steinberg BM. Laryngeal papilloma cells have high levels of epidermal growth factor receptor and respond to epidermal growth factor by a decrease in epithelial differentiation. Cancer Res 1993;53:910-4.
28. Zyzak LL, MacDonald LM, Batova A, et al. Increased levels and constitutive tyrosine phosphorylation of the epidermal growth factor receptor contribute to autonomous growth of human papillomavirus type 16 immortalized human keratinocytes. Cell Growth Differ 1994;5: 537-47.
29. Gullick WJ, Marsden JJ, Whittle N, et al. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulvar carcinomas. Cancer Res 1986;46:285-92.
30. Viac J, Chardonnet Y, Bouvard V, et al. Virus expression, EGF and transferrin receptors in human papillomas. Virchows Arch A Pathol Anat Histopathol 1987;411:73-7.
31. Goppinger A, Wittmaack FM, Wintzer HO, et al. Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias. J Cancer Res Clin Oncol 1989;115:259-63.
32. Yasumoto S, Taniguchi A, Sohma K. Epidermal growth factor (EGF) elicits down-regulation of human papillomavirus type 16 (HPV-16) E6/E7 mRNA at the transcriptional level in an EGF-stimulated human keratinocyte cell line: Functional role of EGF-responsive silencer in the HPV-16 long control region. J Virol 1991;65:2000-9.
33. Merrick DT, McDougall JK. personal communication, 1993.
34. Fuze A, Simizu B, van Ranst M, et al. The induction of IL-6 and gelatinase-B by IL-1 in mouse cell lines transformed with bovine papillomavirus: decreased production in tumorigenic cells. Lymphokine Cytokine Res 1992;11:215-20.
35. Woodworth CD, Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus, and carcinoma cell lines. Am J Pathol 1993;142:1544-55.
36. Malejczyk J, Malejczyk M, Breitburd F, et al. Progressive growth of human papillomavirus type 16-transformed keratinocytes is associated with an increased release of soluble tumour necrosis factor (TNF) receptor. Br J Cancer 1996;74:234-9.
37. Malejczyk J, Malejczyk M, Majewski S, et al. Release of soluble tumor necrosis factor-α (TNF-α) receptor by HPV-associated neoplastic cells. In: Stanley MA, editor. Immunology of human papillomaviruses. New York: Plenum Press, 1994:315-20.
38. Malejczyk M, Jozwiak J, Osiecka A, et al. Serum levels of soluble tumor necrosis factor receptors in patients with benign and malignant HPV-associated anogenital lesions (submitted).
39. Malejczyk M, Jozwiak J, Obalek S, et al. Soluble tumor necrosis factor receptors in patients with benign and malignant cutaneous lesions (submitted).
40. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76:287-99.
41. Lehner PJ, Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr Opin Immunol 1996;8:59-67.
42. Siu G, Springer EA, Hedrick SM. The biology of the T-cell antigen receptor and its role in the skin immune system. J Invest Dermatol 1990;94:91S-100S.
43. Nickoloff BJ, Turka LA, Mitra RS, et al. Direct and indirect control of T-cell activation by keratinocytes. J Invest Dermatol 1995;105:25S-29S.
44. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995;81:979-82.
45. Rattis F-M, Péguet-Navarro J, Staquet M-J, et al. Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Eur J Immunol 1996; 26:449-53.
46. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102:768-73.
47. van Rensburg EJ, van Heerden WF, Raubenheimer EJ. Langerhans cells and human papillomaviruses in oesophageal and laryngeal carcinomas. In Vivo 1993;7:229-32.
48. Bhawan J, Dayal Y, Bhan AK. Langerhans cells in molluscum contagiosum, verruca vulgaris, plantar wart, and condyloma acuminatum. J Am Acad Dermatol 1986;15: 645-9.
49. Viac J, Soler C, Chardonnet Y, et al. Expression of immune associated surface antigens of keratinocytes in human papillomavirus-derived lesions. Immunobiol 1993; 188:392-402.
50. Lehtinen M, Rantala I, Toivonen A, et al. Depletion of Langerhans cells in cervical HPV infection is associated with replication of the virus. AMPIS 1993;101:833-7.
51. Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr Opin Immunol 1996;8:348-54.
52. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
53. Cromme FV, Meijer CJLM, Snijders PJF, et al. Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer 1993;68:1372-80.
54. Glew SS, Duggan-Keen M, Cabrera T, et al. HLA class II antigen expression in human papilloma virus-associated cervical cancer. Cancer Res 1992;52:4009-16.
55. Hilders CG, Houbiers JG, van Ravenswaay-Claasen HH, et al. Associations between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 1993;69:651-9.
56. Morelli AE, Belardi G, DiPaola G, et al. Cellular subsets and epithelial ICAM-1 and HLA-DR expression in human papillomavirus infection of the vulva. Acta Derm Venereol (Stockh) 1994;74:45-50.
57. Nickoloff BJ, Turka LA. Keratinocytes: immunocytes of the integument. Am J Pathol 1993;143:325-31.
58. Norris DA. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol 1990;95:111S-20S.
59. Nickoloff BJ, Turka LA. Immunologic functions of non-professional antigen-presenting cells. New insights from studies of T-cell interaction with keratinocytes. Immunol Today 1994;15:464-9.
60. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71: 1093-102.
61. Engelhard VH. Structure of peptides associated with MHC class I molecules. Curr Opin Immunol 1994;6:13-23.
62. Rötzschke O, FaIk K. Origin, structure and motifs of naturally processed MHC class II ligands. Curr Opin Immunol 1994;6:45-51.
63. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-5.
64. Helland Å, Børresen AL, Kærn J, et al. HLA antigens and cervical carcinoma. Nature 1992;356:23.
65. Gregoire L, Lawrence WD, Kukuruga D, et al. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women. Int J Cancer 1994;57: 504-7.
66. Bonagura VR, O'Reilly ME, Abramson AL, et al. Recurrent respiratory papillomatosis (RRP): enriched HLA DQw3 phenotype and decreased class I MHC expression. In: Stanley MA, editor. Immunology of human papilloma viruses. New York: Plenum Press, 1994:195-8.
67. Apple RJ, Erlich HA, Klitz W, et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature Genet 1994;6:157-62.
68. Bavinck JNB, Gissmann L, Claas FJH, et al. Relation between skin cancer, humoral response to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993;151:1579-86.
69. Ellis JRM, Keating PJ, Baird J, et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Med 1995; 1:464-70.
70. Keating PJ, Cromme FV, Duggan-Keen MF, et al. Frequency of downregulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 1995;72:405-11.
71. Kast MW, Brandt RPM, Drijfhout JW, et al. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. J Immunother 1993;14:115-20.
72. Kast MW, Brandt RPM, Sidney J, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-12.
73. Bartholomew JS, Stacey SN, Coles B, et al. Identification of a naturally processed HLA A0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein. Eur J Immunol 1994;24:3175-9.
74. Tarpey I, Stacey S, Hickling J, et al. Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. Immunology 1994;81: 222-7.
75. Strang G, Hickling JK, McIndoe GAJ, et al. Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity. J Gen Virol 1990;71:423-31.
76. Kadish AS, Romney SL, Ledwidge R, et al. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity in not type-specific. J Gen Virol 1994;75:2277-84.
77. Steele JC, Stankovic T, Gallimore PH. Production and characterization of human proliferative T-cell clones specific for human papillomavirus type 1 E4 protein. J Virol 1993;67:2799-806.
78. Toes REM, Blom RJJ, Offringa R, et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996; 156:3911-8.
79. Reiner SL, Seder RA. T helper cell differentiation in immune response. Curr Opin Immunol 1995;7:360-6.
80. Viac J, Chardonnet Y, Chignol MC, et al. Papilloma viruses, warts, carcinoma and Langerhans cells. In Vivo 1993;7:207-12.
81. Carter LL, Dutton RW. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 1996;8:336-42.
82. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995;71:655-9.
83. Gross G, von Krogh G, Barrasso R. Genitoanal lesions. In: Gross G, von Krogh G, editors. Human papillomavirus infections in dermatovenerology. Boca Raton: CRC Press, 1997:389-416.
84. Arany I, Tyring SK. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions. J Interferon Cytokine Res 1996;16:453-60.
85. Wahl SM. The role of transforming growth factor-beta in inflammatory processes. Immunol Res 1991;10:249-54.
86. Nickoloff BJ, Morhenn V. Keratinocyte-derived soluble factors which influence lymphocyte proliferation. J Invest Dermatol 1988;90:415-6.
87. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
88. Barker JNWN, Mitra RS, Griffits CEM, et al. Keratinocytes as initiators of inflammation. Lancet 1991;337:211-4.
89. Kleine K, König G, Kreutzer J, et al. Expression of the JE (MCP-1) gene encoding the monocyte chemoattractant protein-1 results in partial tumor suppression of HeLa-cells in nude mice. Mol Carcinog 1995;14:179-89.
90. Hilders CGJM, Ras L, van Eendenburg JDH, et al. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994;57:805-13.
91. Chen L, Thomas EK, Hu S-L, et al. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991;88:110-4.
92. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992;148:2617-21.
93. Meneguzzi G, Cerni C, Kieny MP, et al. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991;181:62-9.
94. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
95. Browning MJ, Bodmer WF. MHC antigens and cancer: implications for T-cell surveillance. Curr Opin Immunol 1992;4:613-8.
96. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990;46:1029-34.
97. Hilders CGJM, Houbiers JGA, Krul EJT, et al. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma. Am J Clin Pathol 1994;101:5-12.
98. Torres LM, Cabrera T, Concha A, et al. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens 1993;41: 65-71.
99. Cromme FV, van Bommel PFJ, Walboomers JMM, et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared to the primary tumours. Br J Cancer 1994;69:1176-81.
100. Honma S, Tsukada S, Honda S, et al. Biological-clinical significance of selective loss of HLA-class-1 allelic product expression in squamous-cell carcinoma of the uterine cervix. Int J Cancer 1994;57:650-5.
101. van Driel WJ, Tjiong MY, Hilders CGJM, et al. Association of allele-specific HLA expression and histopatholog-ic progression of cervical carcinoma. Gynecol Oncol 1996;62:33-41.
102. Cromme FV, Snijders PJF, van den Brule AJC, et al. MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression. Oncogene 1993;8:2969-75.
103. Cromme FV, Airey J, Heemels M-T, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
104. Reynolds CW, Wiltrout RH, editors. Functions of the natural immune system. New York: Plenum, 1989.
105. Iwatsuki K, Tagami H, Takigawa M, et al. Plane warts under spontaneous regression. Immunopathologic study on cellular constituents leading to the inflammatory reaction. Arch Dermatol 1986;122:655-9.
106. Syrjänen K, Väyrynen M, Mäntyjärvi R, et al. Natural killer (NK) cells with HNK-1 phenotype in the cervical biopsies of women followed-up for human papillomavirus (HPV) lesions. Acta Obstet Gynecol Scand 1986;65: 139-15.
107. Tay SK, Jenkins D, Singer A. Natural killer cells in cervical intraepithelial neoplasia and human papillomavirus infection. Br J Obstet Gynaecol 1987;94:901-6.
108. Bishop PE, McMillan A, Fletcher S. An immunohistological study of spontaneous regression of condylomata acuminata. Genitourin Med 1990;66:79-81.
109. Malejczyk J, Majewski S, Jablonska S, et al. Abrogated NK-cell lysis of human papillomavirus (HPV)-16-bearing keratinocytes in patients with pre-cancerous and cancerous HPV-induced anogenital lesions. Int J Cancer 1989;43:209-14.
110. Majewski S, Malejczyk J, Jablonska S, et al. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1990;22:243-47.
111. Banks L, Moreau F, Voudsen K, et al. Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. J Immunol 1991;146:2037-42.
112. Raulet DH, Held W. Natural killer cell receptors: the offs and ons of NK cell recognition. Cell 1995;82:697-700.
113. Malejczyk J, Malejczyk M, Majewski S, et al. NK-cell activity in patients with HPV16-associated anogenital tumors: defective recognition of HPV16-harboring keratinocytes and restricted unresponsiveness to immunostimulatory cytokines. Int J Cancer 1993;54:917-21.
114. Evans CH, Flugelman AA, DiPaolo JA. Cytokine modulation of immune defenses in cervical cancer. Oncology 1993;50:245-51.
115. Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 1988;9:58-62.
116. Symington FW, Santos EB. Recognition of keratinocytes by cytotoxic T cells specific for conventional HLA class-I alloantigen. J Invest Dermatol 1990;95:224-8.
117. Symington FW, Santos EB. Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells: keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/ CD18) mediate enhanced lysis of IFN-γ-treated keratinocytes. J Immunol 1991;146:2169-75.
118. Wu R, Coleman N, Higgins G, et al. Lymphocyte-mediated cytotoxicity to HPV16 infected cervical keratinocytes. In: Stanley MA, editor. Immunology of human papillomaviruses. New York: Plenum Press, 1994:255-8.
119. Barnett SC, Evans CH. Leukoregulin-increased plasma membrane permeability and associated ionic fluxes. Cancer Res 1986;46:2686-92.
120. Furbert-Harris PM, Evans CH, Woodworth CD, et al. Loss of leukoregulin upregulation of natural killer but not lymphokine-activated killer lymphocytotoxicity in human papillomavirus 16 DNA-immortalized cervical epithelial cells. J Natl Cancer Inst 1989;81:1080-5.
121. Woodworth CD, Lichti U, Simpson S, et al. Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells. Cancer Res 1992;52:456-63.
122. Berke G. The CTL's kiss of death. Cell 1995;81:9-12.
123. Benton C, Shahidullah H, Hunter J. Human papillomavirus in the immunosuppressed. Papillomavirus Rep 1992;3:23-6.
124. Brown DR, Bryan JT, Cramer H, et al. Detection of multiple human papillomavirus types in condylomata acuminata from immunosuppressed patients. J Infect Dis 1994;170:759-65.
125. Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated lesions. Int J Cancer 1994;57:836-40.
126. Cauda R, Tyring SK, Grossi CE, et al. Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity. J Clin Immunol 1987;7:304-11.
127. Chopra V, Tyring SK. Suppression of interleukin-2 production and activity by factor(s) released by peripheral blood mononuclear cells during papillomavirus infection. Viral Immunol 1991;4:237-48.
128. Haftek M, Jablonska S, Orth G. Specific-cell mediated immunity in patients with epidermodysplasia verruciformis and plane warts. Dermatologica 1985;170:213-20.
129. Majewski S, Skopinska-Rozewska E, Jablonska S, et al. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1986;15:966-75.
130. Kaminski M, Pawinska M, Jablonska S, et al. Increased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol 1985;121:84-6.
131. Cooper KD, Androphy EJ, Lowy D, et al. Antigen presentation and T-cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990;94:769-76.